St. Vincent's Institute of Medical Research
🇦🇺Australia
- Country
- 🇦🇺Australia
- Ownership
- Private
- Established
- 1951-01-01
- Employees
- 101
- Market Cap
- -
- Website
- http://www.svi.edu.au
Clinical Trials
3
Active:2
Completed:1
Trial Phases
2 Phases
Phase 1:1
Phase 2:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 2
2 (66.7%)Phase 1
1 (33.3%)Inhibition of Plasma Kallikrein as a New Therapy for Lung Injury
Phase 1
Active, not recruiting
- Conditions
- Lung Injury
- Interventions
- Other: Saline control
- First Posted Date
- 2021-04-19
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- St Vincent's Institute of Medical Research
- Target Recruit Count
- 48
- Registration Number
- NCT04848272
- Locations
- 🇦🇺
St Vincent's Hospital Melbourne, Melbourne, Victoria, Australia
Baricitinib in New-onset Type 1 Diabetes
- First Posted Date
- 2021-03-01
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- St Vincent's Institute of Medical Research
- Target Recruit Count
- 91
- Registration Number
- NCT04774224
- Locations
- 🇦🇺
Women's and Children's Hospital Adelaide, North Adelaide, South Australia, Australia
🇦🇺St Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia
🇦🇺Royal Melbourne Hospital, Parkville, Victoria, Australia
News
Lilly's Olumiant Shows Promise in Preserving Beta Cell Function in Type 1 Diabetes
Phase 2 BANDIT trial demonstrates Eli Lilly's Olumiant (baricitinib) can slow progression of type 1 diabetes by preserving insulin-producing beta cell function over 48 weeks of treatment.